All Updates

All Updates

icon
Filter
M&A
Reunion Neuroscience to be acquired by MPM BioImpact for USD 13.1 million
Psychedelic Medicine
Jun 1, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Jun 1, 2023

Reunion Neuroscience to be acquired by MPM BioImpact for USD 13.1 million

M&A

  • Toronto-based psychedelic therapy company Reunion Neuroscience has entered an agreement with MPM BioImpact, a biotechnology investment firm, for an all-cash acquisition valued at approximately USD 13.1 million. The transaction will be carried out through a statutory plan of arrangement under the Canada Business Corporations Act. The acquisition is subject to shareholder approval and other conditions.

  • The acquisition by MPM BioImpact will provide Reunion Neuroscience with financial support and strategic partnership opportunities to advance the development of its clinical pipeline and address unmet medical needs in the field of mental health. The transaction is expected to close in Q3 2023.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.